NasdaqGS:SYREBiotechs
Why Spyre Therapeutics (SYRE) Is Up 7.1% After Faster IBD Trial Timelines And New Commercial Chief
In recent updates, Spyre Therapeutics outlined its 2026 plans, highlighting accelerated timelines for six proof-of-concept readouts, including the SKYLINE ulcerative colitis trial completing enrollment earlier than initially expected, and confirmed that the SKYWAY basket trial remains on schedule for later-stage data.
The company also recently appointed Kate Tansey Chevlen as Chief Commercial Officer, signaling a growing emphasis on commercial readiness alongside its advancing inflammatory...